par Moreno, Christophe 
;Berg, Thomas;Tanwandee, Tawesak;Thongsawat, Satawat;Van Vlierberghe, Hans;Zeuzem, Stefan;Lenz, Oliver;Peeters, Monika P.;Sekar, Vanitha;De Smedt, Goedele
Référence Journal of hepatology, 56, 6, page (1247-1253)
Publication Publié, 2012-06
;Berg, Thomas;Tanwandee, Tawesak;Thongsawat, Satawat;Van Vlierberghe, Hans;Zeuzem, Stefan;Lenz, Oliver;Peeters, Monika P.;Sekar, Vanitha;De Smedt, GoedeleRéférence Journal of hepatology, 56, 6, page (1247-1253)
Publication Publié, 2012-06
Article révisé par les pairs
| Résumé : | TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase III development for the treatment of hepatitis C virus (HCV) infection. Phase I and II studies in patients infected with HCV genotype 1 have demonstrated that TMC435 is generally well tolerated, has a pharmacokinetic profile that supports once daily dosing, and demonstrates potent antiviral activity. This phase IIa study (TMC435-C202; NCT00812331) was conducted to investigate the antiviral activity, safety, tolerability, and pharmacokinetics of TMC435 in treatment-naїve patients infected with HCV genotypes 2-6. |
